Table 2.
Distribution of 56 genotype-1 and 40 genotype-3-infected patients by demographic, host and viral factors with respect to response to hepatitis C virus therapy (mean ± SD) n (%)
| Variable |
Genotype 1 (n = 56) |
Genotype 3 (n = 40) |
||||
| Responders(n = 32) | Non-responders(n = 24) | P value | Responders(n = 30) | Non-responders(n = 10) | P-value | |
| Gender | 0.70 | 0.47 | ||||
| Male | 15 (46.9) | 10 (41.7) | 13 (43.3) | 6 (60.0) | ||
| Female | 17 (53.1) | 14 (58.3) | 17 (56.7) | 4 (40.0) | ||
| Age (yr) | 0.17 | 0.15 | ||||
| ≤ 40 | 23 (71.9) | 13 (54.2) | 29 (96.7) | 8 (80.0) | ||
| > 40 | 9 (28.1) | 11 (45.8) | 1 (3.3) | 2 (20.0) | ||
| Body mass index (kg/m2) | 0.28 | 0.42 | ||||
| < 25 | 18 (56.3) | 10 (41.7) | 23 (76.7) | 6 (60.0) | ||
| 25-28 | 14 (43.7) | 14 (58.3) | 7 (23.3) | 4 (40.0) | ||
| Grade of hepatic steatosis | 0.0001 | 0.72 | ||||
| Mild | 22 (68.7) | 5 (20.8) | 12 (40.0) | 3 (30.0) | ||
| Moderate | 10 (31.3) | 12 (50.0) | 13 (43.3) | 4 (40.0) | ||
| Severe | 0 (0.0) | 7 (29.2) | 5 (16.7) | 3 (30.0) | ||
| Fibrosis score | 0.001 | 0.04 | ||||
| 1 | 17 (53.1) | 3 (12.5) | 16 (53.3) | 1 (10.0) | ||
| 2 | 11 (34.4) | 8 (33.3) | 11 (36.7) | 7 (70.0) | ||
| 3-4 | 4 (12.5) | 13 (54.2) | 3 (10.0) | 2 (20.0) | ||
| 5-6 | 0 | 0 | 0 | 0 | ||
| HOMA-IR | 0.01 | 0.01 | ||||
| < 2 | 11 (34.4) | 4 (16.7) | 19 (63.3) | 1 (10.0) | ||
| 2-3 | 10 (31.2) | 2 (8.3) | 10 (33.3) | 7 (70.0) | ||
| > 3 | 11 (34.4) | 18 (75.0) | 1 (3.3) | 2 (20.0) | ||
| Leptin_baseline (ng/mL) | 37.66 ± 10.39 | 49.67 ± 13.44 | 0.001 | 24.33 ± 7.98 | 28.20 ± 9.72 | 0.22 |
| Ghrelin_baseline (ng/mL) | 0.286 ± 0.167 | 0.190 ± 0.119 | 0.02 | 0.778 ± 0.654 | 0.564 ± 0.324 | 0.18 |
| Leptin end of follow-up (ng/mL) | 26.69 ± 11.77 | 41.50 ± 16.24 | < 0.0001 | 23.27 ± 9.54 | 26.70 ± 6.82 | 0.30 |
| Ghrelin end of follow-up (ng/mL) | 0.456 ± 0.254 | 0.239 ± 0.213 | 0.001 | 0.420 ± 0.321 | 0.450 ± 0.261 | 0.79 |
HOMA-IR: Homeostasis model assessment insulin resistance.